AMR / MDR pipeline

Ilya Pharma's lead assets are complemented by a pipeline of non-disclosed assets addressing AMR/MDR for the yet untapped opportunity of eliminating pan-resistant bacterial infections with lactic acid bacteria, addressing the WHO critical MDR pathogens.